Retrieve available abstracts of 50 articles: HTML format
Single Articles
July 2025
BURTON EM, Milton DR, Tetzlaff MT, Wani K, et al Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant
Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable
Melanoma.
J Clin Oncol. 2025 Jul 10:JCO2500494. doi: 10.1200/JCO-25-00494. PubMedAbstract available
WONG MK, Milhem MM, Sacco JJ, Michels J, et al RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).
J Clin Oncol. 2025 Jul 8:101200JCO2501346. doi: 10.1200/JCO-25-01346. PubMedAbstract available
June 2025
MARQUEZ-RODAS I, Dutriaux C, Saiag P, de la Cruz Merino L, et al BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced
Melanoma: Phase II Clinical Trial SPOTLIGHT-203.
J Clin Oncol. 2025 Jun 27:JCO2402595. doi: 10.1200/JCO-24-02595. PubMedAbstract available
DIAB A, Ascierto PA, Maio M, Abdel-Wahab R, et al Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination
With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory
Melanoma (ILLUMINATE-301).
J Clin Oncol. 2025 Jun 25:JCO2501412. doi: 10.1200/JCO-25-01412. PubMed
MCCLELLAND PH, Nah SK, Gustafson AM, Dinerman AJ, et al Adoptive Cell Transfer of Tumor-Infiltrating Lymphocytes for Metastatic Acral
Lentiginous Melanoma.
J Clin Oncol. 2025 Jun 13:JCO2402348. doi: 10.1200/JCO-24-02348. PubMedAbstract available
LODDE GC, Hassel JC, von Wasielewski I, Meier F, et al Long-term follow-up of real-world adjuvant anti-PD1 checkpoint inhibition and
targeted therapy in stage III melanoma patients.
J Clin Oncol. 2025 Jun 3:101200JCO2402776. doi: 10.1200/JCO-24-02776. PubMedAbstract available
MEDINA T, Chesney JA, Kluger HM, Hamid O, et al Long-term Efficacy and Safety of Lifileucel Tumor-infiltrating Lymphocyte (TIL)
Cell Therapy in Patients with Advanced Melanoma: A 5-year Analysis of the
C-144-01 Study.
J Clin Oncol. 2025 Jun 2:101200JCO2500765. doi: 10.1200/JCO-25-00765. PubMedAbstract available
April 2025
SPERDUTO PW, Marqueen KE, Chang E, Li J, et al Improved Survival and Prognostication in Melanoma Patients With Brain Metastases:
An Update of the Melanoma Graded Prognostic Assessment.
J Clin Oncol. 2025 Apr 17:JCO2401351. doi: 10.1200/JCO-24-01351. PubMedAbstract available
March 2025
LONG GV, Lipson EJ, Hodi FS, Ascierto PA, et al Erratum: First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in
Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and
CheckMate 067 Trial Data.
J Clin Oncol. 2025 Mar 7:JCO2500452. doi: 10.1200/JCO-25-00452. PubMed
DIAB A, Ascierto PA, Maio M, Abdel-Wahab R, et al Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With
Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma
(ILLUMINATE-301).
J Clin Oncol. 2025 Mar 6:JCO2400727. doi: 10.1200/JCO.24.00727. PubMedAbstract available
WEISS SA, Djureinovic D, Wei W, Tran T, et al Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated
Melanoma Brain Metastases.
J Clin Oncol. 2025 Mar 6:JCO2402219. doi: 10.1200/JCO-24-02219. PubMedAbstract available
February 2025
PATEL SP, Sheth RA, Davis C, Medina T, et al Combination Immunotherapy With Nivolumab Plus Ipilimumab in Melanoma of Unknown
Primary.
J Clin Oncol. 2025 Feb 6:JCO2401802. doi: 10.1200/JCO-24-01802. PubMedAbstract available
January 2025
ROTZ SJ, Stratton K, Leisenring WM, Smith SA, et al Melanoma Among Adult Survivors of Childhood Cancer: A Report From the Childhood
Cancer Survivor Study.
J Clin Oncol. 2025 Jan 8:JCO2401519. doi: 10.1200/JCO-24-01519. PubMedAbstract available
HUANG RY, Youssef G, Nelson T, Wen PY, et al Comparative Analysis of Intracranial Response Assessment Criteria in Patients
With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in
CheckMate 204.
J Clin Oncol. 2025 Jan 3:JCO2400953. doi: 10.1200/JCO.24.00953. PubMedAbstract available
December 2024
TAWBI HA, Hodi FS, Lipson EJ, Schadendorf D, et al Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma
From RELATIVITY-047.
J Clin Oncol. 2024 Dec 13:JCO2401124. doi: 10.1200/JCO.24.01124. PubMedAbstract available
November 2024
LONG GV, Larkin J, Schadendorf D, Grob JJ, et al Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in
Patients With Advanced Melanoma.
J Clin Oncol. 2024 Nov 6:JCO2400400. doi: 10.1200/JCO.24.00400. PubMedAbstract available
KREFT S, Lorigan P Combination Immunotherapy for Advanced Melanoma-How to Choose?
J Clin Oncol. 2024 Nov 4:JCO2402005. doi: 10.1200/JCO-24-02005. PubMed
VERHEIJDEN RJ, de Groot JS, Fabriek BO, Hew MN, et al Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor
Efficacy: Analysis of Six Clinical Trials.
J Clin Oncol. 2024;42:3713-3724. PubMedAbstract available
October 2024
WEBER JS, Middleton MR, Yates G, Sharpe DJ, et al Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV
Melanoma: Analyses From CheckMate 238 and European Organization for Research and
Treatment of Cancer 18071 Trials.
J Clin Oncol. 2024 Oct 8:JCO2400237. doi: 10.1200/JCO.24.00237. PubMedAbstract available
SCHMITT AM, Larkin J, Patel SP Dual Immune Checkpoint Inhibition in Melanoma and PD-L1 Expression: The Jury Is
Still Out.
J Clin Oncol. 2024 Oct 7:JCO2401572. doi: 10.1200/JCO-24-01572. PubMedAbstract available
MARGOLIN KA Using Indirect Comparisons of Prospective, Randomized Trials to Make Therapeutic
Decisions in Melanoma: Cross-Trial Comparisons as Surrogates for Proper
Head-To-Head Studies?
J Clin Oncol. 2024 Oct 7:JCO2401634. doi: 10.1200/JCO-24-01634. PubMed
SARGEN MR, Barnhill RL, Elder DE, Swetter SM, et al Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical
Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's
Oncology Group.
J Clin Oncol. 2024 Oct 4:JCO2401154. doi: 10.1200/JCO.24.01154. PubMedAbstract available
September 2024
VALLEJO BA, Ansari A, Parikh SA, Achenbach SJ, et al Risk of Incident Melanoma Among Individuals With Low-Count Monoclonal B-Cell
Lymphocytosis.
J Clin Oncol. 2024 Sep 4:JCO2400332. doi: 10.1200/JCO.24.00332. PubMedAbstract available
August 2024
LONG GV, Lipson EJ, Hodi FS, Ascierto PA, et al First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced
Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067
Trial Data.
J Clin Oncol. 2024 Aug 13:JCO2401125. doi: 10.1200/JCO.24.01125. PubMedAbstract available
WEBER J, Del Vecchio M, Mandala M, Gogas H, et al Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint
Inhibitor Treatment for Resected Melanoma in CheckMate 238.
J Clin Oncol. 2024 Aug 5:JCO2301448. doi: 10.1200/JCO.23.01448. PubMedAbstract available
July 2024
HARBOUR JW, Correa ZM, Schefler AC, Mruthyunjaya P, et al 15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal
Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2
(COOG2.1).
J Clin Oncol. 2024 Jul 25:JCO2400447. doi: 10.1200/JCO.24.00447. PubMedAbstract available
June 2024
HAMID O, Lewis KD, Weise A, McKean M, et al Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3)
Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma.
J Clin Oncol. 2024 Jun 20:JCO2302172. doi: 10.1200/JCO.23.02172. PubMedAbstract available
March 2024
SCHENK KM, Deutsch JS, Chandra S, Davar D, et al Nivolumab + Tacrolimus + Prednisone +/- Ipilimumab for Kidney Transplant Recipients
With Advanced Cutaneous Cancers.
J Clin Oncol. 2024;42:1011-1020. PubMedAbstract available
LUKE JJ, Ascierto PA, Khattak MA, de la Cruz Merino L, et al Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC
Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III
KEYNOTE-716 Study.
J Clin Oncol. 2024 Mar 7:JCO2302355. doi: 10.1200/JCO.23.02355. PubMedAbstract available
February 2024
Expression of Concern: Dissecting Therapeutic Resistance to RAF Inhibition in
Melanoma by Tumor Genomic Profiling.
J Clin Oncol. 2024 Feb 23:JCO2400161. doi: 10.1200/JCO.24.00161. PubMed
VAREY AHR, Li I, El Sharouni MA, Simon J, et al Predicting Recurrence-Free and Overall Survival for Patients With Stage II
Melanoma: The MIA Calculator.
J Clin Oncol. 2024 Feb 5:JCO2301020. doi: 10.1200/JCO.23.01020. PubMedAbstract available
Erratum: Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor
Genomic Profiling.
J Clin Oncol. 2024 Feb 1:JCO2400017. doi: 10.1200/JCO.24.00017. PubMed
December 2023
DE VIS JB, Cmelak AJ, Osmundson EC Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: Systemic Before
Local Therapy?
J Clin Oncol. 2023 Dec 11:JCO2302151. doi: 10.1200/JCO.23.02151. PubMed
DIAB A, Gogas H, Sandhu S, Long GV, et al Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label,
Phase III PIVOT IO 001 Trial Results.
J Clin Oncol. 2023 Aug 31:JCO2300172. doi: 10.1200/JCO.23.00172. PubMedAbstract available
HARGRAVE DR, Terashima K, Hara J, Kordes UR, et al Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF
V600-Mutant Pediatric High-Grade Glioma.
J Clin Oncol. 2023 Aug 29:JCO2300558. doi: 10.1200/JCO.23.00558. PubMedAbstract available
SETH R, Agarwala SS, Messersmith H, Alluri KC, et al Systemic Therapy for Melanoma: ASCO Guideline Update.
J Clin Oncol. 2023 Aug 14:JCO2301136. doi: 10.1200/JCO.23.01136. PubMedAbstract available
Retraction: Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma.
J Clin Oncol. 2023 Aug 11:JCO2301358. doi: 10.1200/JCO.23.01358. PubMed
July 2023
ASCIERTO PA, Dummer R, Gogas HJ, Arance A, et al Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of
BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS
Trial.
J Clin Oncol. 2023 Jul 28:JCO2202322. doi: 10.1200/JCO.22.02322. PubMedAbstract available
ZHANG X, Ferris L, Faries MB, Luke JJ, et al Debating Sentinel Lymph Node Biopsy for Melanoma in the Modern Adjuvant Era.
J Clin Oncol. 2023 Jul 6:JCO2300255. doi: 10.1200/JCO.23.00255. PubMed
June 2023
ROBERT C, Carlino MS, McNeil C, Ribas A, et al Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus
Ipilimumab in Advanced Melanoma.
J Clin Oncol. 2023 Jun 22:JCO2201599. doi: 10.1200/JCO.22.01599. PubMedAbstract available
OLSON DJ, Odunsi K Adoptive Cell Therapy for Nonhematologic Solid Tumors.
J Clin Oncol. 2023;41:3397-3407. PubMedAbstract available
DUMMER R, Corrie P, Gutzmer R, Meniawy TM, et al First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in
Clinically Diverse Patient Populations With Unresectable Stage III or IV
Melanoma: CheckMate 401.
J Clin Oncol. 2023 Jun 12:JCO2202199. doi: 10.1200/JCO.22.02199. PubMedAbstract available
RIELY GJ, Smit EF, Ahn MJ, Felip E, et al Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With
BRAF(V600)-Mutant Metastatic Non-Small-Cell Lung Cancer.
J Clin Oncol. 2023 Jun 4:JCO2300774. doi: 10.1200/JCO.23.00774. PubMedAbstract available
April 2023
LONG GV, Menzies AM, Scolyer RA Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now.
J Clin Oncol. 2023 Apr 27:JCO2202575. doi: 10.1200/JCO.22.02575. PubMedAbstract available
March 2023
DE BRAUD F, Dooms C, Heist RS, Lebbe C, et al Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib
in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label
Study.
J Clin Oncol. 2023 Mar 22:JCO2202018. doi: 10.1200/JCO.22.02018. PubMedAbstract available
PHADKE MS, Smalley KSM Targeting NRAS Mutations in Advanced Melanoma.
J Clin Oncol. 2023 Mar 22:JCO2300205. doi: 10.1200/JCO.23.00205. PubMed
OLOFSSON BAGGE R, Nelson A, Shafazand A, All-Eriksson C, et al Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal
Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial
(the SCANDIUM Trial).
J Clin Oncol. 2023 Mar 20:JCO2201705. doi: 10.1200/JCO.22.01705. PubMedAbstract available
Erratum: Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma
With Confirmed Progression on a Programmed CellDeath Protein-1 or Programmed
Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
J Clin Oncol. 2023 Mar 20:JCO2300439. doi: 10.1200/JCO.23.00439. PubMed
Erratum: COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of
Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With
BRAF V600-Mutant Melanoma.
J Clin Oncol. 2023 Mar 8:JCO2300385. doi: 10.1200/JCO.23.00385. PubMed